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SUMMARY.-Oral potassium permanganate has been used in the manage-
ment of terminal carcinoma in three patients. Symptomatic improvement
occurred in all three, with elimination of oral foetor in one patient and dimin-
ished requirement of analgesics in the other two. The mental state of each
patient was improved and normal activities were resumed.
STROUD, the " Birdman of Alcatraz ", demonstrated (Gaddis, 1956) that a
suitable antiseptic used as a whole body detergent could enable the host to over-
come the deleterious effects ofapathogen. Byusing oxidising agents he succeeded
in eliminating viral infection from birds. There is now more recent evidence
(Lund, 1966) that oxidising agents may also have a direct inactivating action on
someviruses.
Potassium permanganate is not toxic to human beings when used in small
doses, except when it is administered for very long periods. It has proved useful
in the management of patients with carcinoma in whom other methods of treat-
ment had been unable to give symptomatic relief. These patients were in the
terminal stages of the disease and had such troublesome symptoms that life was
absolutely miserable.
CASE REPORTS
Ccase I
A 71-year-old woman had a left-sided mandibulectomy in 1967 for squamous
cell carcinoma of floor of mouth. The carcinoma recurred following a course of
post-operative radiotherapy and she was readmitted in July 1969, with an inoper-
able lesion. There was infiltration oftongue, cervicallymphnodes andthe contra-
lateral mandibular region. A further short course of radiotherapy produced no
improvement.
Her most troublesome symptom was a strong smell which caused distress not
only to the patient and her relatives but also to the other occupants of the ward.
A capsule containing 260 mg. ofcrystalline potassium permanganate was given
orally three times daily and within 48 hours the oral foetor was abolished and the
patient became brighter and more active. Her appetite improved as well. After
two months, treatment was discontinued for one week and the nauseating foetor
recurred with all its distressing effects. Treatment was recommenced (in fact, it
was demanded by her daughter) and her foetor was again controlled satisfactorily.
At the present time, there is still oedema ofthe tongue and a fistula through the
lip, but the primary growth has become softer in consistency and the grosslyPOTASSIUM PERMANGANATE IN TERMINAL CARCINOMA
enlarged submandibular nodes have diminished in size and are now barely palp-
able. The patient has remained reasonably comfortable and free of odour for
six months while under treatment with potassium permanganate.
Case II
A 58-year-old man was admitted on the 16th October, 1969, with abdominal
pain and gross hepatomegaly. Laparotomy revealed multiple metastases in the
liver due to an anaplastic carcinoma, possibly bronchial in origin. The patient
had constant epigastric and right hypochondrial pain which was not alleviated by
analgesics, including opiates. The quantity ofdrugs administered during a typical
day is illustrated in Table 1.
TABLE I. Daily Intake of Analgesics (Case II)
Before treatment After treatment
8.30 p.m. . Morphine 10 mg. i.m.
10.00 a.m. Brompton Cocktail . Methadone 5 mg. orally.
15 ml. orally.
+ Methadone 5 mg. orally.
11. 30 p.m. . DF 118 two tablet orally
1. 00 p.m. Morphine 10 mg. i.m.
2. 00 p.m. Brompton Cocktail 15 ml.
orally.
4.00 p.m. DF 118 two tablets orally.
6. 00 p.m. . Brompton Cocktail . Methadone 5 mg. orally.
15 ml. orally.
+ Morphine 10 mg.
+ Methadone 5 mg.
orally.
10. 00 p.m. . Morphine 10 mg. i.m. . Morphine 10 mg. i.m.
Oral potassium permanganate was commenced in a dosage of 260 mg. t.i.d.,
given in capsule form. Within 48 hours, there was a considerable improvement
in the condition of the patient. Pain was no longer constant but occurred for
only an hour or two each day and it was easily controlled by analgesic drugs.
The daily intake ofanalgesics decreased (Table I) and the patient became cheerful
and more comfortable. The E.S.R. fell from 110 mm. to 80 mm. per hour and the
alkaline phosphatase, from 105 KA units to 80 KA units. The patient was
discharged home after 6 weeks treatment and he is now comfortable and able to
go out, although there is no evidence of any regression of the tumour itself.
Case III
A 45-year-old lady was found at laparotomy on October 28, 1969, to have an
inoperable carcinoma of pancreas. The tumour was anaplastic and she experi-
enced severe painintheepigastrium andthelumbarregion. Pain was incompletely
relieved by drugs and the heavy doses of opiates (Table II) made the patient
confused, drowsy and bedridden.
Oral potassium permanganate was given in a dosage of 130 mg. t.i.d. and within
48 hours there was considerable improvement inthe patient's condition. Although
her nervous disposition created difficulties in assessment of the effects of the
treatment, the difference in the intake of analgesics on a typical day before and
after treatment with potassium permanganate was impressive (Table II).
When treatment was interrupted for 24 hours, her pain resumed its previous
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TABLE II.-Daily Intake ofAnalgesics (Case III)
Before treatment After treatment
12.30 a.m. Morphine 15 mg. i.m.
5.00 a.m. . Morphine 15 mg. i.m.
8.00 a.m. . Palfuim tablet one orally
10.00 a.m. . Fortral 25 mg. . Codeine 2 tablets
10. 15 a.m. . Palfuim tablet one orally
1.00 p.m. Omnopon 20 mg. i.m.
+ 50 m.g. Valloid.
2. 00 p.m. . Fortral 25 mg.
4. 00 p.m. . Omnopon 20 mg. i.m. . Codeine 2 tablets
5. 00 p.m. Brompton Cocktail 15 ml.
9.00 p.m. . Omnopon 20 mg. i.m.
10.00 p.m. Brompton Cocktail 15 ml. . Morphine 10 mg. i.m.
severity and was inadequately controlled by morphine. Potassium perman-
ganate was again administered with further symptomatic relief and she is now
alert, comfortable and ambulant. The E.S.R. decreased from 105 mm. to 30 mm.
per hour during a period of six weeks.
DISCUSSION
Potassium permanganate is a strong oxidising agent. In solution it readily
releases nascent oxygen, which is responsible for the antiseptic properties (Alstead,
1960). By oxidising the cellular proteins of micro-organisms, potassium perman-
ganate inhibits their growth and activity. Similarly it reacts with organic
matter and facilitates the disintegration of necrotic tissue. For these reasons, it
is often used for irrigating abscess cavities, wounds and the lower urinary tract.
From the limited experience reported here, it appears that potassium perman-
ganate has a similar action when administered systemically. It is possible that
oxidation of necrotic tissue and acidic metabolites eliminated oral foetor in the
first patient and decreased the severity of pain in the other two.
Warburg (1931) demonstrated glycolysis in animal tumours and postulated
that malignant change was brought about by hypoxia. Although the role of
anoxia in the aetiology of neoplasia is not fully understood, recent evidence
suggests that hyperbaric oxygen makes the malignant cells more sensitive to
radiotherapy (Churchill-Davidson et al., 1955). Unfortunately, hyperbaric
oxygen cannot be given at high pressures because of the harmful side-effects,
especially on the central nervous system (Donald, 1947). It is possible that
potassium permanganate may affect tumour growth by oxidising the products of
glycolysis.
Potassium permanganate has few toxic effects when given orally in a dosage
of 260 mg. t.i.d. However, it does produce nausea in most patients and, for this
reason, should be given in an enteric coated capsule to ensure that it is not released
in the stomach. This diminishes the incidence and severity of nausea and the
only other alimentary side-effects which may occur is constipation.
If potassium permanganate is given in large doses or for long periods, degener-
ative changes may occur in the brain, liver, myocardium and lungs. The patient
may develop convulsions, ectopic heart beats, respiratory failure or hepatic
failure (Hunter, 1969).
In the presence ofa tumour, there may be preferential uptake by the neoplasm,
which would lessen the possibility of toxic effects. None of the three patients
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treated had evidence oftoxicitybutallhadintermittent nausea and one complained
of constipation. No other side-effects of the treatment were noted.
CONCLUSIONS
Oral administration of potassium permanganate in patients with inoperable
carcinoma can lead to symptomatic improvement, and, possibly, a reduction in
the quantity of analgesic drugs required to control pain.
It is doubtful whether potassium permanganate has any direct effect on the
tumour itself, but this aspect certainly merits further investigation.
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this study on their patients. I am also grateful to Mr. Blackwood, the Chief
Pharmacist at Stobhill General Hospital, Glasgow, and his staff for the help they
provided in preparing the capsules and standardising the dosage. I amfurther
indebted to Professor W. A. Mackey, for encouragement and guidance. Last, but
not least, my thanks go to Mr. J. K. Watt and Dr. G. Dow (Department of
Anaesthesia) for the helpful criticism they provided during the preparation of
this article.
REFERENCES
ALSTEAD, S.-(1960) Dilling's Clinical Pharmacology. London (Cassell & Co., Ltd.)
p.515.
CHURCHILL-DAVIDsON, I., SANGER, C. AND THOMLINSON, R. H.-(1955) Lancet, i, 1091.
DONALD, K. W.-(1947) Br. med. J., i, 667.
GADDIS, T. E.-(1956) 'The Birdman of Alcatraz'. London (Victor Gollanez Ltd.).
HUNTER, D.-(1969) 'The Diseases ofOccupations'. London (The English Universities
Press Ltd.) p. 459.
LUND, E.-(1966) Arch. ges. Virusforsch., 19, 32.
WARBURG, O.-(1931) 'Metabolism of Tumours'. New York (R. R. Smith, Inc.).